ADC Therapeutics SA Q3 2025 Earnings Recap

ADCT Q3 2025 November 10, 2025

Get alerts when ADCT reports next quarter

ADC Therapeutics reported steady net product revenues of $15.8 million in Q3 2025, reflecting consistent demand for its lead product, ZENLATA, while positioning for future growth through ongoing clinical trials and recent financing.

Earnings Per Share Beat

$-0.30 vs $-0.40 est.

+25.0% surprise

Revenue Miss

16427000 vs 21569170 est.

-23.8% surprise

Market Reaction

1-Day -5.7%

5-Day -5.7%

30-Day -0.71%

See ADCT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Net product revenues were stable, matching quarterly run rates from the previous two years.
Secured a $60 million private placement, extending the cash runway into 2028.
Multiple ongoing clinical trials for ZENLATA are expected to bolster its market position, with potential expansions into earlier treatment lines and additional lymphoma types.
Anticipation for upcoming data releases from key trials, including LOTUS V and LOTUS seven, which could enhance revenue projections significantly.
Long-term peak annual revenue for ZENLATA is estimated between $600 million and $1 billion, contingent on successful trial outcomes and market expansion.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ADCT on AllInvestView.

Previous Q2 2025